Evaluation of urinary proepithelin as a potential biomarker for bladder cancer detection and prognosis in Egyptian patients

Selmy, Mohamed; Ibrahim, Gehan H.; Serafi, Taher I. El; Ghobeish, A.

doi:10.3233/cbm-2010-0186

Cited by 11 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, there is a positive correlation between urinary progranulin mRNA and protein. This is in agreement with the study of (Selmy et al, 2010) who found that progranulin levels in voided urine samples from bladder cancer patients was significantly higher in patients with malignant lesions compared to healthy individuals (Selmy et al, 2010).…”

Section: Discussionsupporting

confidence: 93%

“…This is same specificity but a higher sensitivity result than the study of (Selmy et al, 2010) that revealed that measuring urinary progranulin level test has a test sensitivity and specificity to detect the presence of bladder cancer as 74.6 and 85.2%, respectively. Both studies are just preliminary studies that needed further researches to fully test effectiveness of measuring progranulin urinary level as a sensitive and specific test for cancer bladder.…”

Section: Discussionmentioning

confidence: 62%

See 1 more Smart Citation

Role of Progranulin Gene Expression as a Molecular Biomarker for Bladder Cancer

Anas¹

2012

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

Bladder cancer is the second most common cancer of the urinary system. Early diagnosis of this tumor and estimation of risk of future progression has a significant impact on prognosis. Although there are several molecular markers for the diagnosis and prognosis for this tumor, their accuracy is not ideal. Progranulin is a growth factor that may play a critical role in bladder cancer. Previous reports have shown that progranulin is essential for cellular proliferation. In this study, we examined whether progranulin gene expression can be a novel molecular marker for bladder cancer and evaluated its potential suitability as a urinary biomarker for bladder cancer diagnosis. Expression of progranulin gene in tissue and urine sediment of normal and bladder cancer samples was performed by semi-quantitative reverse transcription-PCR. Also, progranulin level was estimated in 90 voided urine samples, including 65 bladder cancer patients and 25 healthy volunteers using the quantitative enzyme immunoassay technique. Significant over-expression of progranulin was observed in bladder cancer cases. This over-expression was correlated with the stage and grade of the cancer. The urinary progranulin level was significantly higher in bladder cancer patients compared to control subjects (means: 18.39±0.56 and 9.17±0.41 ng mL −1 , respectively; p<0.001). Furthermore, the urinary progranulin level at cut off value = 11.275 has a sensitivity = 93.8% and a specificity = 84% for cancer bladder diagnosis. Urinary progranulin may be considered as a simple, noninvasive test with acceptable sensitivity and specificity for bladder cancer diagnosis and may greatly improve the current diagnosis based on cytology. However, this is a preliminary study that opens the window for further researches to fully validate its results in progranulin and cancer bladder research.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 62%

Role of Progranulin Gene Expression as a Molecular Biomarker for Bladder Cancer

Anas¹

2012

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

show abstract

“…PGRN mRNA expression levels was higher in high-grade bladder cancer than that of low-grade bladder cancer, and overexpression of PGRN were observed in patients who died after 5 years of follow-up compared with those alive after 5 years of follow-up treatment [41,42]. PGRN levels in voided urine samples from bladder cancer patients revealed that PGRN level was significantly higher in patients with malignant lesions compared to healthy individuals [43].…”

Section: Ovarian Cancermentioning

confidence: 89%

The Glycoprotein Growth Factor Progranulin Promotes Carcinogenesis and has Potential Value in Anti-cancer Therapy

Zhang¹

2012

J Carcinogene Mutagene

View full text Add to dashboard Cite

Progranulin (PGRN) is a secreted glycoprotein growth factor with tumorigenic roles in a variety of tumors including, among others, breast, ovarian, prostate, bladder, and liver cancer. In some patients, for example with breast, ovarian or liver cancers, high PGRN expression in tumors correlated with a worse outcome. Studies using cell lines and animal models provide evidence that PGRN promotes tumor cell proliferation, migration and survival, and induces drug resistance. Increasing or decreasing PGRN production enhances or inhibits respectively the growth of PGRN-sensitive tumors in vivo. PGRN activity is associated with p44/42 mitogen-activated protein kinase as well as phosphatidylinositol 3-kinases signaling pathways. In addition, PGRN may stimulate the formation of the tumor stroma. As an extracellular regulator of tumorgenesis, PGRN is a potential therapeutic target and biomarker of prognosis in the treatment of various cancers.

show abstract

“…Also, in the same study, tissue samples from patients with renal cell carcinoma show higher levels of PGRN expression compared with low-grade renal cell carcinoma and normal tissue [84]. In patients with bladder cancer, urinary levels of PGRN are significantly increased relative to control samples; in addition, high PGRN levels correlate with the stage and pathological cancer grade [85]. Unfortunately, the small sample size of this study is a limitation; however, the results suggest that urine PGRN levels may serve as a simple test as part of a bladder cancer work-up.…”

Section: Progranulin As Cancer Biomarkermentioning

confidence: 96%

Progranulin and its biological effects in cancer

et al. 2017

View full text Add to dashboard Cite

Cancer cells have defects in regulatory mechanisms that usually control cell proliferation and homeostasis. Different cancer cells share crucial alterations in cell physiology, which lead to malignant growth. Tumorigenesis or tumor growth requires a series of events that include constant cell proliferation, promotion of metastasis and invasion, stimulation of angiogenesis, evasion of tumor suppressor factors, as well as avoidance of cell death pathways. All these events in tumor progression may be regulated by growth factors produced by normal or malignant cells. The growth factor progranulin has significant biological effects in different types of cancer. This protein is a regulator of tumorigenesis because it stimulates cell proliferation, migration, invasion, angiogenesis, malignant transformation, resistance to anticancer drugs, and immune evasion. This review focuses on the biological effects of progranulin in several cancer models and provides evidence that this growth factor should be considered as a potential biomarker and target in cancer treatment.

show abstract

Evaluation of urinary proepithelin as a potential biomarker for bladder cancer detection and prognosis in Egyptian patients

Abstract: This preliminary study suggests that urinary proepithelin may be considered as a non-invasive, sensitive, and specific urine-based test for bladder cancer diagnosis and/or prognosis.

Cited by 11 publications

References 24 publications

Role of Progranulin Gene Expression as a Molecular Biomarker for Bladder Cancer

Role of Progranulin Gene Expression as a Molecular Biomarker for Bladder Cancer

The Glycoprotein Growth Factor Progranulin Promotes Carcinogenesis and has Potential Value in Anti-cancer Therapy

Progranulin and its biological effects in cancer

Contact Info

Product

Resources

About